Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02301104 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment
A Phase 1 study, sponsored by Taiho Oncology.
- Completed
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
NCT02301104 is a Phase 1 study that has completed, run by Taiho Oncology. The registered enrollment target is 24 participants.
The verdict
NCT02301104, a Phase 1 study, has completed, sponsored by Taiho Oncology.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
Study Summary
Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of hepatic impairment.
Interventions
- DRUG TAS-102
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2015-01 |
| Est. Completion | 2016-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02301104
The ClinicalTrials.gov registry entry for NCT02301104 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Taiho Oncology, which has 52 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which TAS-102 is the first listed.
NCT02301104 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02301104 about?
NCT02301104 is a clinical study titled "A Phase I Study of TAS-102 in Patients With Advanced Solid Tumors With Hepatic Impairment". Study to evaluate the safety, tolerability, and pharmacokinetics of TAS-102 in patients with advanced solid tumors and varying degrees of hepatic impairment.
What is the current status of trial NCT02301104?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2015-01. Estimated completion is 2016-06.
What interventions are being tested in trial NCT02301104?
The interventions under investigation include: TAS-102 (DRUG).
Who is sponsoring clinical trial NCT02301104?
This trial is sponsored by Taiho Oncology, which has 52 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.